Shareholder Alert: Robbins LLP Informs Investors of the Tempus AI, Inc. Class Action

Core Viewpoint - A class action lawsuit has been filed against Tempus AI, Inc. for allegedly misleading investors regarding its business prospects and financial reporting [1][2]. Allegations - The lawsuit claims that Tempus inflated the value of contract agreements, many of which were with related parties and included non-binding opt-ins or were self-funded [2] - Concerns were raised about the credibility of Tempus' joint venture with SoftBank, suggesting it appeared to involve "round-tripping" capital to create revenue [2] - The business model of Tempus-acquired Ambry is said to be based on aggressive and potentially unethical billing practices, risking scrutiny and sustainability [2] - AstraZeneca reportedly reduced its financial commitments to Tempus through a questionable "pass-through payment" arrangement [2] - These issues indicate weaknesses in Tempus' core operations and revenue prospects [2]. Management and Financial Reporting Concerns - A report by Spruce Point Capital Management highlighted several red flags regarding Tempus' management and operations, including a history of executives cashing out before public shareholders incur losses [3] - The report claims that Tempus' actual AI capabilities are overstated and that there are signs of aggressive accounting and financial reporting [3] - Issues with the AstraZeneca and Pathos AI deal were noted as requiring further scrutiny [3] - Recent financial guidance from the company suggests weaknesses in core operations [3]. Stock Price Impact - Following the news of the allegations and the report, Tempus' stock price fell by $12.67 per share, or 19.23%, from $65.87 to $53.20 on May 28, 2025 [4].